The US FDA has awarded orphan drug designation to arGentis Pharmaceuticals' ARG 201 [native type 1 bovine collagen] for use in systemic scleroderma.

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1625, 2008-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

US FDA grants orphan drug designation for imisopasem manganese

By  

Inpharma, Vol. 1, Iss. 1629, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

US orphan drug designation granted for MGCD0103

By  

Inpharma, Vol. 1, Iss. 1626, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

STX 100 receives orphan drug designation in the US.

By  

Inpharma, Vol. 1, Iss. 1652, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Orphan drug designation in the EU

By  

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

The European Commission has granted orphan drug designation to CytRx Corporation's arimoclomol for the treatment of amyotrophic lateral sclerosis

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite